Benzinga · Aug 20, 2026
Edesa Biotech Stock Sinks After Fresh Capital Raise
Edesa Biotech Stock falls in premarket trading as investors weigh a $25 million offering, new warrants and potential dilution.
ED
NASDAQ · EDSA
Edesa Biotech, Inc.
Healthcare · Biotechnology
$3.87
Down-$0.25 (-6.07%)
Updated Sep 17, 2026, 9:22 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.31M
- P/E ratio
- -2.08
- Dividend yield
- 0.00%
- 52-week range
- $0.72 – $20.32
- Volume
- 94.42K
- Avg. volume
- 340.05K
Price performance
EDSA price history
1M range · 20 trading sessions · Daily adjusted prices
EDSA closed at $3.87 after 20 trading sessions, down 32.70% for the selected period.
- Last close
- $3.87
- Period change
- -32.70%
- Period low
- $3.87
- Period high
- $5.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $4.08 | $4.12 | $3.8395 | $3.87 | 94.42K |
| Sep 15, 2026 | $4.18 | $4.35 | $4.06 | $4.12 | 35.01K |
| Sep 14, 2026 | $4.28 | $4.435 | $4.03 | $4.135 | 54.25K |
| Sep 11, 2026 | $4.70 | $4.8404 | $4.23 | $4.23 | 26.79K |
| Sep 10, 2026 | $4.80 | $4.90 | $4.6382 | $4.66 | 40.24K |
| Sep 9, 2026 | $4.79 | $5.10 | $4.72 | $4.72 | 32.14K |
| Sep 8, 2026 | $4.69 | $4.91 | $4.69 | $4.73 | 32.03K |
| Sep 4, 2026 | $4.72 | $4.969 | $4.72 | $4.73 | 36.38K |
| Sep 3, 2026 | $4.74 | $4.87 | $4.69 | $4.76 | 26.23K |
| Sep 2, 2026 | $4.81 | $5.0532 | $4.76 | $4.76 | 29.81K |
| Sep 1, 2026 | $4.78 | $5.0099 | $4.61 | $4.78 | 24.18K |
| Aug 31, 2026 | $4.70 | $4.94 | $4.45 | $4.735 | 91.75K |
| Aug 28, 2026 | $4.65 | $4.9259 | $4.5019 | $4.62 | 70.66K |
| Aug 27, 2026 | $4.97 | $4.978 | $4.60 | $4.60 | 81.26K |
| Aug 26, 2026 | $4.50 | $5.10 | $4.40 | $4.94 | 235.3K |
| Aug 25, 2026 | $4.39 | $4.75 | $4.28 | $4.45 | 112.05K |
| Aug 24, 2026 | $4.45 | $4.60 | $4.12 | $4.40 | 101.56K |
| Aug 21, 2026 | $4.50 | $4.95 | $4.17 | $4.43 | 156.24K |
| Aug 20, 2026 | $5.19 | $6.00 | $4.50 | $4.76 | 391.91K |
| Aug 19, 2026 | $5.71 | $6.00 | $5.61 | $5.75 | 119.83K |
Latest EDSA news
The latest Smart Investors Daily articles mentioning EDSA.
Stock researchCompany · Overview
EDSA research
Overview
Company profile and research snapshot.
Company profile
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 28, 2024 | HC Wainwright & Co. | Buy | — |
| Feb 14, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Edesa Biotech Commences Common Stock Offering; Terms Undisclosed
Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced
Benzinga · Mar 6, 2026
Edesa Biotech shares are trading higher after CEO Pardeep Nijhawan bought 10,000 shares at an average price of $3.63 per share. That purchase brought the CEO's weekly buying to 23,000 shares this week, increasing his stake to about 1.37 million shares.
Benzinga · Mar 3, 2026
12 Health Care Stocks Moving In Tuesday's Intraday Session
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
